SNX17 protects the heart from doxorubicin-induced cardiotoxicity by modulating LMOD2 degradation

Zhang Y, Ni L, Lin B, Hu L, Lin Z, Yang J, Wang J, Ma H, Liu Y, Yang J, Lin J, Xu L, Wu L, Shi D.

Pharmacological Research, 2021


Antitumor drugs, such as doxorubicin, are still widely used in anti-cancer treatments even though the cardiotoxicity is a significant cause of heart failure.  In this paper, the authors explored the role of SNX17 in DOX-induced cardiotoxicity.  Evaluation of SNX17 interference in vivo and in vitro (using the Maestro microelectrode array platform) with DOX-treatment showed worsened damage and increased susceptibility to DOX-induced cardiotoxicity.  The pathway affected exacerbated DOX-induced systolic dysfunction.  Overall, the results found that SNX17 plays a protective role in DOX-induced cardiotoxicity.